{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:55:04Z","timestamp":1789584904447,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ando.2025.101735","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:07:47Z","timestamp":1746724067000},"page":"101735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer"],"prefix":"10.1016","volume":"86","author":[{"given":"Christine","family":"Do Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Godbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Bardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Borson-Chazot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Decaussin-Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Wassermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Lugat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Leboulleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9rang\u00e8re","family":"Narciso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hadoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9gol\u00e8ne","family":"Hescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Buffet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Lamartina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2025.101735_bib0275","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","article-title":"Definition and management of radioactive iodine-refractory differentiated thyroid cancer","volume":"2","author":"Schlumberger","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2025.101735_bib0280","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beem.2017.04.014","article-title":"Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer","volume":"31","author":"Tuttle","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101735_bib0285","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1089\/thy.2011.0535","article-title":"The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland","volume":"22","author":"Nixon","year":"2012","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0290","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ando.2025.101735_bib0295","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","article-title":"2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.ando.2025.101735_bib0300","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.101735_bib0305","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1089\/thy.2015.0395","article-title":"Time Course and Predictors of Structural Disease Progression in Pulmonary Metastases Arising from Follicular Cell-Derived Thyroid Cancer","volume":"26","author":"Sabra","year":"2016","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0315","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.3390\/diagnostics11122189","article-title":"Prognostic Role of 2-[18F]FDG PET\/CT Metabolic Volume Parameters in Patients Affected by Differentiated Thyroid Carcinoma with High Thyroglobulin Level, Negative 131I WBS and Positive 2-[18F]-FDG PET\/CT","volume":"11","author":"Albano","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.ando.2025.101735_bib0320","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO Classification of Thyroid Neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ando.2025.101735_bib0325","doi-asserted-by":"crossref","first-page":"1437360","DOI":"10.3389\/fonc.2024.1437360","article-title":"Multidisciplinary Canadian consensus on the multimodal management of high-risk and radioactive iodine-refractory thyroid carcinoma","volume":"14","author":"Ezzat","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ando.2025.101735_bib0330","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1634\/theoncologist.2015-0107","article-title":"Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas","volume":"21","author":"Wassermann","year":"2016","journal-title":"The Oncologist"},{"key":"10.1016\/j.ando.2025.101735_bib0335","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/cncr.23515","article-title":"Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma","volume":"113","author":"Rivera","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2025.101735_bib0340","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/ERC-16-0546","article-title":"Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma","volume":"24","author":"Morandi","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2025.101735_bib0345","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/PAP.0000000000000184","article-title":"Aggressive Variants of Papillary Thyroid Carcinoma: Hobnail, Tall Cell, Columnar, and Solid","volume":"25","author":"Nath","year":"2018","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.ando.2025.101735_bib0350","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/PAS.0b013e3180309e6a","article-title":"Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach","volume":"31","author":"Volante","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ando.2025.101735_bib0355","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ando.2025.101735_bib0360","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2025.101735_bib0365","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bulcan.2021.06.009","article-title":"[Molecular genotyping in refractory thyroid cancers in 2021: When, how and why?. A review from the TUTHYREF network]","volume":"108","author":"de la Fouchardi\u00e8re","year":"2021","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.ando.2025.101735_bib0370","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1002\/cncr.30690","article-title":"Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma","volume":"123","author":"Sabra","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2025.101735_bib0375","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/EJE-15-0296","article-title":"Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors","volume":"173","author":"Song","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101735_bib0380","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00259-022-05697-w","article-title":"Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival","volume":"49","author":"Jannin","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ando.2025.101735_bib0385","doi-asserted-by":"crossref","unstructured":"Alfonso Sagnella, Helene Lasolle, Yann Godbert, Christine Do Cao, Delphine Drui, Hescot Segolene, et al. PRONOSThyC: prognostic factors in radioiodine refractory differentiated thyroid cancer with distant metastases, a multicentric study from the French ENDOCAN-TUTHYREF network 2024.","DOI":"10.1530\/endoabs.101.OP-12-04"},{"key":"10.1016\/j.ando.2025.101735_bib0390","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","article-title":"A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer","volume":"29","author":"Leboulleux","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ando.2025.101735_bib0395","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1158\/1078-0432.CCR-22-0437","article-title":"Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study","volume":"28","author":"Weber","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ando.2025.101735_bib0400","first-page":"1124","article-title":"MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer","volume":"33","author":"Leboulleux","year":"2023","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0405","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1089\/thy.2019.0143","article-title":"Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol","volume":"29","author":"Iravani","year":"2019","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0410","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/thy.2023.0456","article-title":"Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers","volume":"34","author":"Toro-Tobon","year":"2024","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0415","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1089\/thy.2021.0524","article-title":"Redifferentiating Effect of Larotrectinib in NTRK-Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer","volume":"32","author":"Groussin","year":"2022","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0420","doi-asserted-by":"crossref","first-page":"e144847","DOI":"10.1172\/JCI144847","article-title":"NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake","volume":"131","author":"Lee","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2025.101735_bib0425","first-page":"330","article-title":"Redifferentiation of a RET-Fusion, Radioiodine-Refractory, Differentiated Thyroid Cancer with Selpercatinib: Flip-Flop Between [18F]FDG PET\/CT and 131I Posttreatment Scanning","volume":"66","author":"Barbry","year":"2025","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1016\/j.ando.2025.101735_bib0430","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bulcan.2019.04.012","article-title":"The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF\u00ae network review","volume":"106","author":"de la Fouchardiere","year":"2019","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.ando.2025.101735_bib0435","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ando.2025.101735_bib0440","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.101735_bib0445","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2025.101735_bib0450","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1089\/thy.2023.0553","article-title":"A Prospective Cohort Study Exploring the Effect of Lenvatinib Planned Drug Holidays in Treatment of Differentiated Thyroid Cancer","volume":"34","author":"Tahara","year":"2024","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0455","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1530\/ERC-18-0049","article-title":"Prolonged duration of response in lenvatinib responders with thyroid cancer","volume":"25","author":"Gianoukakis","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2025.101735_bib0460","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1002\/cncr.34493","article-title":"Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial","volume":"128","author":"Brose","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2025.101735_bib0465","first-page":"1531","article-title":"Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0470","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/thy.2022.0054","article-title":"Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study","volume":"33","author":"Kim","year":"2023","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0475","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamaoncol.2021.6268","article-title":"Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial","volume":"8","author":"Lin","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ando.2025.101735_bib0480","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1158\/1078-0432.CCR-22-3613","article-title":"Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer","volume":"29","author":"Lin","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ando.2025.101735_bib0485","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1158\/1078-0432.CCR-22-3406","article-title":"Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial","volume":"29","author":"Chi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2025.101735_bib0490","doi-asserted-by":"crossref","first-page":"102380","DOI":"10.1016\/j.ctrv.2022.102380","article-title":"Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era","volume":"106","author":"Capdevila","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ando.2025.101735_bib0495","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2025.101735_bib0500","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-Altered Thyroid Cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.101735_bib0505","article-title":"Pralsetinib in Patients with Advanced\/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study","author":"Subbiah","year":"2023","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0510","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2025.101735_bib0515","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ando.2025.101735_bib0520","first-page":"1184","article-title":"Dabrafenib Versus Dabrafenib+Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0525","first-page":"467","article-title":"A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan","volume":"34","author":"Tahara","year":"2024","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.ando.2025.101735_bib0530","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.34657","article-title":"Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study","volume":"129","author":"Oh","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2025.101735_bib0535","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-23-3417","article-title":"Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers","volume":"30","author":"French","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ando.2025.101735_bib0540","doi-asserted-by":"crossref","first-page":"S1033","DOI":"10.1016\/j.annonc.2023.09.1149","article-title":"1920MO Regomune: A phase II study of regorafenib+avelumab in solid tumors - Results of the advanced or metastatic gastrointestinal stromal tumors (mGIST) cohort","volume":"34","author":"Cousin","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000342662500054X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000342662500054X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T12:50:07Z","timestamp":1751028607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000342662500054X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S000342662500054X"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2025.101735","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2025.101735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101735"}}